Citi Remains Buyers of Intercept Pharmaceuticals (ICPT) But Lowers PT to $475
Tweet Send to a Friend
Citi analyst Jonathan Eckard cut his price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $475.00 (from $693.00) but maintained a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
